Embecta (NASDAQ:EMBC – Get Free Report) will likely be releasing its Q4 2026 results before the market opens on Tuesday, November 24th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $267.37 million for the quarter. Individuals can check the company’s upcoming Q4 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 24, 2026 at 8:00 AM ET.
Embecta Stock Down 3.3%
NASDAQ EMBC opened at $6.25 on Tuesday. Embecta has a 52 week low of $2.77 and a 52 week high of $14.81. The company has a 50 day moving average price of $5.98 and a 200 day moving average price of $6.17. The firm has a market cap of $354.12 million, a PE ratio of 3.15 and a beta of 0.81.
Insider Activity at Embecta
In other Embecta news, Director Milton Mayo Morris sold 6,293 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $5.88, for a total transaction of $37,002.84. Following the transaction, the director owned 53,828 shares in the company, valued at approximately $316,508.64. This represents a 10.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.30% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on EMBC
Embecta Company Profile
Embecta is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals. The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business’s history of developing injection devices for diabetes care. Embecta serves customers in markets around the world.
Further Reading
- Five stocks we like better than Embecta
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
